<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480686</url>
  </required_header>
  <id_info>
    <org_study_id>H&amp;H_Neutrino Therapy</org_study_id>
    <nct_id>NCT02480686</nct_id>
  </id_info>
  <brief_title>Neutrino Regimen for Treatment-experienced HCV GT1 Patients</brief_title>
  <official_title>Efficacy and Safety of Neutrino Therapy for Chronic HCV Genotype 1b Treatment-experienced Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanity &amp; Healthy GI and Liver Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Humanity &amp; Healthy GI and Liver Centre</source>
  <oversight_info>
    <authority>Hong Kong: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of NEUTRINO regimen in Chinese chronic HCV
      genotype 1b treatment-experienced patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>Post treatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as HCV RNA &lt; lower limit of quantification (LLOQ) 12 weeks after last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events leading to permanent discontinuation of study drug(s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HCV RNA From Baseline to Week 12</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with on-treatment virologic breakthrough and relapse</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>SOF+PEG+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with HCV genotype 1b infection will receive Sofosbuvir (SOF) 400 mg +PEG+RBV for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF+PEG+RBV</intervention_name>
    <description>Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg).</description>
    <arm_group_label>SOF+PEG+RBV</arm_group_label>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>Sovaldi®</other_name>
    <other_name>Pegasys®</other_name>
    <other_name>Copegus®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age equal to or greater than 18 years, with chronic genotype 1b infection;

          2. HCV RNA equal to or greater than 10,000 IU/mL at Screening;

          3. Cirrhosis determination;

          4. Subjects who are treatment-experienced;

          5. Screening laboratory values within defined thresholds;

          6. Use of highly effective contraception methods if female of childbearing potential or
             sexually active male.

        Exclusion Criteria:

          1. HIV or chronic hepatitis B virus (HBV) infection;

          2. Contraindications for PEG or RBV therapy;

          3. Hematologic or biochemical parameters at Screening outside the protocol-specified
             requirements;

          4. Active or recent history (≤ 1 year) of drug or alcohol abuse;

          5. Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin
             cancers);

          6. Chronic use of systemic immunosuppressive agents;

          7. History or current evidence of any condition, therapy, laboratory abnormality or
             other circumstance that might confound the results of the study, or interfere with
             the subject's participation for the full duration of the study, such that it is not
             in the best interest of the subject to participate.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Lau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanity and Health GI and Liver Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guofeng Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>302 Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yudong Wang, PhD</last_name>
    <phone>(852)28184300</phone>
    <email>ydwang@connect.hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liver Fibrosis Diagnosis and Treatment Centre, 302 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guofeng Chen, MD</last_name>
      <phone>(8610)66933427</phone>
      <email>guofengchen302@163.com</email>
    </contact>
    <investigator>
      <last_name>George KK Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guofeng Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanity and Health GI and Liver Centre</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <zip>00852</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George KK Lau, MD</last_name>
      <phone>(852)28613777</phone>
      <email>gkklau@netvigator.com</email>
    </contact>
    <investigator>
      <last_name>George KK Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 22, 2015</lastchanged_date>
  <firstreceived_date>June 21, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
